References for this Review were identified through searches of PubMed with the search terms “neuropathological diagnosis”, “Parkinson's disease”, “neuropathologic”, “neuropathology”, “criteria”, “autopsy”, and “Parkinson” up to July, 2009. The criteria were based on diagnostic principles of the Parkinson's Disease Society Brain Bank criteria and the Gellb criteria. Additional references were identified from major neuropathology textbooks.
ReviewNeuropathological assessment of Parkinson's disease: refining the diagnostic criteria
Introduction
In contrast to other major neurodegenerative disorders there have been few attempts to provide a standard operating procedure for the neuropathological diagnosis of Parkinson's disease (PD). In this Review, we discuss methodological, molecular, and genetic considerations in making a neuropathological diagnosis of PD that could help in developing guidelines for tissue assessment and could provide a framework to refine standardisation of the neuropathological diagnosis of this disorder.
By focusing on the pathological substrate of clinical parkinsonian syndromes, morphological descriptions are limited to the currently available techniques; furthermore, any observation at postmortem examination is often an imperfect fit with the clinical syndrome. In most cases, attribution of particular clinical features to a given pathological finding is not possible. Consequently, modern neuropathological diagnostic criteria frame diagnosis as a description of the findings and suggest a probabilistic statement about the likelihood that those findings are associated with a particular clinical syndrome.1, 2 This approach is adopted and the prevalence of mixed pathologies considered because a comprehensive assessment of concomitant pathologies is necessary, as has been described for degenerative dementias.3
Section snippets
Molecular classification of parkinsonian disorders
Most available evidence suggests that the neurobiological substrate of the extrapyramidal motor features of parkinsonian disorders is due to nigrostriatal dopaminergic degeneration.4 The morphological correlate of this degeneration is neuronal loss in the pars compacta of the substantia nigra (SNpc), particularly in the ventrolateral tier of neurons in this area.5 When moderate to severe neuronal loss is found in the SNpc, this pathology is usually associated with clinical features consistent
Neuropathological criteria for PD diagnosis
The most common parkinsonian syndrome is sporadic PD. In this disorder, the essential neuropathology is moderate to severe neuronal loss in the SNpc associated with Lewy pathology;46, 47 however, there has never been a formal standard operating procedure or validation for the routine assessment of neuronal loss, even though morphometric assessment of this loss has been confirmed in PD by several groups.48, 49 Neuronal loss in PD most often predominantly affects the ventrolateral area of the
Future directions
The recommended criteria are provisional and need to be validated. Ideally, validation studies would be based on the determination of the reliability, sensitivity, and specificity of the neuropathological diagnostic criteria by a group of neuropathologists65, 66 or by prospective evaluation of patients at postmortem examination, with clinical observations close to the time of death. Such examinations of the neuropathological and genetic basis of PD are likely to provide greater understanding of
Conclusions
Standardisation of the neuropathological diagnostic criteria for PD is the first step in the process of increasing the reliability and validity of its diagnosis. Neuropathological validation studies to refine these criteria and proposed suggestions for neuropathology research will help us further understand what causes the pathogenesis of PD, which we hope will improve the biological therapeutic interventions that can slow or stop disease progression.
Search strategy and selection criteria
References (93)
- et al.
Familial parkinsonism: study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes
Parkinsonism Relat Disord
(2009) - et al.
Nosology of Parkinson's disease: looking for the way out of a quagmire
Neuron
(2005) - et al.
Extensive axonal Lewy neurites in Parkinson's disease: a novel pathological feature revealed by alpha-synuclein immunocytochemistry
Neurosci Lett
(1999) - et al.
Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology
Am J Pathol
(2000) - et al.
Multiple-system atrophy: a new alpha-synuclein disease?
Lancet
(1998) Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are alpha-synucleinopathies
Parkinsonism Relat Disord
(1999)- et al.
Staging of brain pathology related to sporadic Parkinson's disease
Neurobiol Aging
(2003) - et al.
Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology
Neurosci Lett
(2006) The morphological basis of mental dysfunction in Parkinson's disease
J Neurol Sci
(2006)- et al.
Relationship between Parkinson disease with dementia and dementia with Lewy bodies
Parkinsonism Relat Disord
(2005)